Supernus Pharmaceuticals and Indivior Pharmaceuticals completed their merger on November 2, 2026, creating Supernus, Inc. (Nasdaq: SUPN) with an 11-product central nervous system (CNS) portfolio ...

Eton Pharmaceuticals licensed Baylor's IGF-1 patent rights to develop ET-900, extending INCREL for infantile and epileptic ...

FDA clears US IND for Alphamab's dual-payload EGFR/HER3 ADC JSKN021, opening its first trial outside China. Read on to learn ...

Leads Biolabs dosed the first lupus patient in its Phase I LBL-047 trial, marking the fusion protein’s first use in ...

Alligator Bioscience agrees to sell its CD40 agonist mitazalimab to Biossil for $0.75M upfront and up to $109M. Explore full ...

Bambusa Therapeutics (Nasdaq: BBTX) priced an upsized IPO of 10.6M shares at $16, raising $168.9M to fund BBT001 atopic ...

AbbVie expands its Brise migraine license with two preclinical programs worth up to $757M. Read the deal details and what it means for migraine patients.

Karyopharm files Chapter 11 and names Ayrmid lead bidder in a court-supervised sale. Read how Ayrmid's bid affects its marketed drugs, pipeline and team.

EMA and Japan's MHLW accept savolitinib plus osimertinib filings for MET-driven EGFR lung cancer. Read the full details on this regulatory milestone today.

Sun Pharma's Ilumya (tildrakizumab-asmn) is now FDA-approved for adults with active psoriatic arthritis. Learn how this expands its psoriasis use today.

FDA pushes back mitapivat sickle cell disease sNDA decision to February 1, 2027. Read how the REMS review affects Agios' PYRUKYND and what comes next.

Qure's AMT-130 Huntington's gene therapy has FDA Priority Review under Accelerated Approval, with a May 1, 2027 decision date. Read the details now.